News

Connecticut biotech shows resilience amid recent layoffs at Arvinas, RallyBio
Job cuts at home-grown pharma companies like Arvinas and RallyBio and federal policies challenge CT biotech 'ecosystem' that ...
MyChesCo on MSN9d
Annovis Bio Advances Phase 3 Alzheimer’s Trial Amid Steady Financial Progress
MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) unveiled significant progress in its efforts to combat neurodegenerative diseases ...
Nasdaq14d
Annovis Bio Inc. Provides Corporate Updates and Q1 2025 Financial Results, Initiates Pivotal Phase 3 Clinical Trial for Alzheimer’s Disease
Annovis Bio Inc., a company focused on developing therapies for neurodegenerative diseases, announced updates on May 13, 2025. The first quarter was highlighted by the launch of a pivotal Phase 3 ...
Yahoo Finance14d
Annovis Provides Corporate Updates and Reports First Quarter 2025 Financial Results
Malvern, Pa., May 13, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for ...
Investing28d
Annovis Bio hires new director of biostatistics amid AD trial
MALVERN, Pa. - Annovis Bio Inc. (NYSE: ANVS), a clinical-stage biotech company with a $30.2 million market capitalization focusing on developing treatments for neurodegenerative diseases, announced ...
Mena FN28d
Annovis Bio Appoints Hui Liu As Director Of Biostatistics
(MENAFN- GlobeNewsWire - Nasdaq) MALVERN, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical ...
Investing28d
Annovis Bio hires new director of biostatistics amid AD trial
MALVERN, Pa. - Annovis Bio Inc. (NYSE: ANVS), a clinical-stage biotech company with a $30.2 million market capitalization focusing on developing treatments for neurodegenerative diseases ...
Yahoo Finance28d
Annovis Bio Appoints Hui Liu as Director of Biostatistics
MALVERN, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company developing transformative therapies for ...
ETF Daily News1mon
Annovis Bio (ANVS) Projected to Post Quarterly Earnings on Friday
Annovis Bio (NYSE:ANVS – Get Free Report) is anticipated to issue its quarterly earnings data before the market opens on Friday, April 4th. Analysts expect the company to announce earnings of ($ ...
Yahoo Finance2mon
Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE
MALVERN, Pa., March 27, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative ...
Business Insider2mon
Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results
MALVERN, Pa., March 21, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for ...
Fintel on MSN3mon
D. Boral Capital Downgrades Annovis Bio (ANVS)
Fintel reports that on February 10, 2025, D. Boral Capital downgraded their outlook for Annovis Bio (NYSE:ANVS) from Buy to Hold. Analyst Price Forecast Suggests 1,107.35% Upside As of January 28 ...